MétaCan
Menu
Back to cohort
Record W2318376928 · doi:10.1093/neuonc/nou256.26

GE-27 * THERAPEUTIC IMPLICATIONS OF MEDULLOBLASTOMA SUBGROUPS IN CHILDREN OVER AGE 3: A SINGLE CENTRE POPULATION BASED EXPERIENCE

2014· article· en· W2318376928 on OpenAlexaffabout
Viraraghavan Vadakkencherry Ramaswamy, Marc Remke, J. Adamski, Ute Bartels, Uri Tabori, Allen Huang, Michael D. Taylor, Éric Bouffet

Bibliographic record

VenueNeuro-Oncology · 2014
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsHospital for Sick Children
Fundersnot available
KeywordsMedicineMedulloblastomaCohortInternal medicineProgression-free survivalOverall survivalPopulationOncologyChemotherapyRadiation therapyCohort studySurvival analysisPediatricsPathology

Abstract

fetched live from OpenAlex

OBJECTIVES: The advent of integrated genomics has fundamentally changed our understanding of medulloblastoma. Although survival differences have been shown to exist between the four principle subgroups, treatment related differences have yet to be elucidated. We sought to delineate these differences at a large referral centre. METHODS: All patients over age 3 treated with surgery, craniospinal irradiation and adjuvant chemotherapy were identified at the Hospital for Sick Children in Toronto from 1998-2012. RESULTS: Ninety-four patients were identified who met our inclusion criteria. Two periods were identified, those patients treated prior to 2006 as per the open protocols of the Children's Oncology Group (CCG9961, POG9631), and patients treated after 2006 treated as per the SJMB03 protocol. Five-year progression free survival over the entire cohort was 78%. When stratified by treatment, 5 year survival pre and post 2006 were identical (76.8% pre-2006 and 79.3% post-2006). When re-analysed in a subgroup specific manner, we find no significant differences in progression-free survival pre and post 2006. Strikingly, we found that Group 3 and 4 patients have excellent survivals compared to those previously reported, with 5 year progression-free survival in average risk Group 4 patients of over 90% and over 75% in average risk Group 3 patients regardless of treatment protocol. SHH patients did relatively poorly across both treatment protocols with 5 year progression free survival of 60% likely owing to a high proportion of TP53 mutated patients. CONCLUSIONS: In a cohort of homogenously treated patients over age 3, progression free survival appears to be improved compared to initial reports based on retrospective cohorts. The impact of subgroup affiliation in children over age 3 needs to assessed in large prospectively treated cooperative protocols to determine the subgroup specificity of treatment regiments.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.016
Threshold uncertainty score0.032

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0010.000
Scholarly communication0.0000.000
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.018
GPT teacher head0.291
Teacher spread0.273 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2014
Admission routes2
Has abstractyes

Explore more

Same venueNeuro-OncologySame topicGlioma Diagnosis and TreatmentFrench-language works237,207